Brief: Biostage posts Q2 loss per share $0.17

Harvard Apparatus Regenerative Technology

11/08/2016 12:52

Aug 11 (Reuters) - Biostage Inc  BSTG.O  
    * Biostage reports 2016 second quarter financial results and 
provides business update outlining key near-term milestones 
    * Qtrly revenues $28,000 versus $73,000  
    * Q2 loss per share $0.17 
    * Expect to commence human clinical studies of esophageal 
implant in h1 2017 
    * On track to file IND for esophageal implant before year 
end 
 
Source text for Eikon:  ID:nPn9lWdv5a  
Further company coverage:  BSTG.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))